Qihan Biotech's QT-019B Receives FDA RMAT and BTD

Qihan Biotech announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for QT-019C, a universal dual-target CAR-T candidate, marking a significant milestone in the development of a potentially optimized low-lymphodepletion, off-the-shelf CAR-T therapy for autoimmune diseases

Qihan Biotech Initiates Dosing in Phase I/IIa Clinical Trial with Off-the-Shelf Allogeneic CAR-T Therapy for Refractory Systemic Lupus Erythematosus